Controlled release implants for cardiovascular disease

Keyphrases

• Controlled Release 100%
• Cardiovascular Disease 100%
• Controlled Release Matrix 100%
• Controlled Release System 100%
• Drug Concentration 50%
• Release Rate 50%
• Drug Release 50%
• Disease Status 50%
• Lactic Acid 50%
• Innovative Design 50%
• Gentamicin 50%
• Drug Dosing 50%
• Design Features 50%
• Systemic Dose 50%
• High Molecular Weight 50%
• Heart Valve Prosthesis 50%
• Cardiovascular System 50%
• Matrix System 50%
• Drug Therapy 50%
• Adverse Drug Effects 50%
• Silicone Rubber 50%
• Scar Tissue Formation 50%
• Pathological Calcification 50%
• Non-biodegradable Polymer 50%
• Epicardial 50%
• Systemic Therapy 50%
• Drug Choice 50%
• Polyurethane 50%
• Electrical Pacing 50%
• Ethylene Vinyl Acetate 50%
• Polyanhydride 50%
• Normal Sinus Rhythm 50%
• Valvular Endocarditis 50%
• Reservoir Configuration 50%
• Glycolic 50%
• Cardiac Lead 50%
• Pacing Threshold 50%
• Closed-loop Feedback 50%
• Biodegradable Compounds 50%
• Heart Valve Leaflet 50%
• Lidocaine HCl 50%
• Ventricular Tachycardia 50%

Pharmacology, Toxicology and Pharmaceutical Science

• Controlled Release 100%
• Cardiovascular Disease 100%
• Endocarditis 16%
• Dexamethasone 16%
• Ethylene Vinyl Acetate Copolymer 16%
• Clinical Study 16%
• Pharmacotherapy 16%
• Drug Concentration 16%
• Drug Release 16%
• Adverse Drug Reaction 16%
• Gentamicin 16%
• Lidocaine 16%
• Implant 16%
• Lactic Acid 16%
• Diseases 16%
• Polyanhydride 16%
• Polyurethan 16%
• Silastic 16%
• Etidronic Acid 16%
• Heart Ventricle Tachycardia 16%